利培酮对男性精神分裂症患者骨密度的影响

发布时间：2018-04-06 03:40

本文选题：非典型抗精神病药　切入点：利培酮　出处：《大连医科大学》2012年硕士论文

【摘要】：目的：了解非典型抗精神病药物利培酮对男性精神分裂症患者骨密度的影响。方法：采用《测量骨密度影响因素调查问卷》对60例男性精神分裂症患者(研究组)以及60例男性健康体检人群(对照组)的一般情况进行调查，收集可能影响骨密度的因素。两组人群在年龄分布上无差异，研究组人群利培酮服药史(x±s，年)4.412±2.554，病史(x±s，年)5.396±2.826。应用双能X线骨密度测量仪对两组人群进行骨密度测定，采用双变量相关分析研究精神分裂症患者骨密度与各因素的相关性，，采用多因素逐步回归方法分析各因素对骨密度的影响。结果：两组人群在体重指数、吸烟程度、饮用牛奶以及运动上存在差异(P＜0.05)。两组骨密度值存在显著差异(p=0.000)，研究组骨密度值明显低于对照组。利培酮服药史(r=-0.811, p=0.000)、病史(r=-0.812, p=0.000)、年龄(r=-0.289, p=0.027)、吸烟程度(r=-0.275, p=0.035)与研究组人群骨密度呈现负相关，运动(r=0.261,p=0.045)与骨密度呈现正相关。多因素逐步回归分析显示利培酮服药史对骨密度影响最大，依次为年龄、运动，其中利培酮服药史(β=-0.712, p=0.000)与年龄(β=-0.377,p=0.000)对骨密度呈现负性作用，运动(β=0.109, p=0.096)对骨密度存在正性作用。结论：精神分裂症患者骨密度值与健康人群相比显著降低，骨密度值降低程度与骨质疏松症罹患人数均较健康人群高。其中药物史是影响精神分裂症患者骨密度的显著因素，长期服用利培酮可以导致患者骨密度值的降低，同时随着年龄的增长也可以增加患者骨量流失的风险。在选择用药上要慎重，尤其对于老年患者及病史较长的患者，要注意预防由药物引发的骨密度损伤的风险。
[Abstract]:Objective: to investigate the effect of atypical antipsychotic risperidone on bone mineral density (BMD) in male schizophrenic patients.Methods: the general situation of 60 male schizophrenic patients (study group) and 60 male healthy people (control group) were investigated by questionnaire on the influencing factors of bone mineral density (BMD), and the possible factors affecting BMD were collected.There was no difference in age distribution between the two groups. In the study group, the history of risperidone administration was x 卤s, the history of risperidone was 4.412 卤2.554, the history of disease was x 卤s, and the age of risperidone was 5.396 卤2.826.Dual energy X-ray absorptiometry was used to measure bone mineral density (BMD) in the two groups. The correlation between BMD and various factors in schizophrenia patients was studied by bivariate correlation analysis.Multivariate stepwise regression method was used to analyze the influence of various factors on bone mineral density (BMD).Results: there were significant differences in body mass index, smoking degree, milk consumption and exercise between the two groups (P < 0.05).There was significant difference in BMD between the two groups, and the BMD in the study group was significantly lower than that in the control group.The history of risperidone administration was negatively correlated with bone mineral density (BMD) of the study group (r = 0.261, P = 0.045), while the history of risperidone was r = -0.811, p = 0.000, r = 0.812, P = 0.000, age = r = 0.289, p = 0.027, smoking degree = r = 0.275, p = 0.035).Multivariate stepwise regression analysis showed that risperidone medication history had the greatest influence on BMD, followed by age and exercise. Among them, Risperidone medication history (尾 -0.712, p0. 000) and age (尾 -0. 377p0. 000) had negative effects on BMD, while exercise (尾 -0.109, p0. 096) had a positive effect on BMD.Conclusion: bone mineral density (BMD) of schizophrenic patients was significantly lower than that of healthy subjects, and the degree of BMD decrease and the number of osteoporosis patients were higher than that of healthy people.Drug history is a significant factor affecting bone mineral density in schizophrenic patients. Taking risperidone for a long time can lead to the decrease of bone mineral density and increase the risk of bone loss with age.We should be careful in the choice of medication, especially for the elderly patients and patients with a long history, we should pay attention to the prevention of drug-induced BMD injury risk.
【学位授予单位】：大连医科大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R749.3

【参考文献】